For research use only. Not for therapeutic Use.
BCI ((E)-BCI) is a DUSP6 (dual specificity phosphatase 6) inhibitor. BCI shows anti-inflammatory activity and decreases reactive oxygen species (ROS) production. BCI can be used in inflammatory disease research[1][2].
BCI (100 ng/mL; 24 h) downregulats the expression of DUSP6 in RAW264.7 macrophage cells[2].?
BCI (0-1 nM; 24 h) inhibits the expression of IL-1β and IL-6 in lipopolysaccharide- (LPS-) activated macrophages[2].?
BCI (0-4 nM; 24 h) decreases ROS production and activates the Nrf2 Pathway in LPS-activated macrophages[2].
| Catalog Number | I017887 |
| CAS Number | 1245792-51-1 |
| Molecular Formula | C22H23NO |
| Purity | ≥95% |
| Reference | [1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45. [2]. Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. |
